PMID: 6977610Mar 1, 1982Paper

Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers

The Journal of Experimental Medicine
R Korngold, J Sprent

Abstract

Evidence is presented that T cells that produce lethal graft-vs.-host disease (GVHD) to minor histocompatibility antigens (minor HA) comprise discrete subgroups of H-2K- and H-2D-restricted T cells; double negative selection of T cells in irradiated H-2 recombinant mice was used to separate these two subgroups. No evidence could be found that I-restricted T cells contributed to GVHD, either as effector cells or helper cells. The (unprimed) precursor cells for GVHD expressed the Thy-1+, Lyt-1+/-2, Ia- phenotype. Studies in which H-2-semiallogeneic bone marrow chimeras were used as hosts for negative selection suggested that presentation of minor HA to T cells during the induction phase is controlled by marrow-derived cells; indirect evidence was obtained that these latter cells can "process" minor HA presented on H-2 different cells and thereby render the antigens immunogenic. Studies in which minor HA-different, H-2-compatible chimeras were re-irradiated and then injected with donor-vs.-host T cells suggested that the effector phase of lethal GVHD involves contact of antigen on non-marrow-derived cells.

References

Jan 1, 1977·Immunological Reviews·H Cantor, E A Boyse

❮ Previous
Next ❯

Citations

Jul 1, 1988·Transplant International : Official Journal of the European Society for Organ Transplantation·D MaraninchiG Novakovitch
Dec 10, 2003·Experimental Hematology·Warren D Shlomchik
Oct 11, 2003·Experimental Hematology·Ulrich DuffnerJames L M Ferrara
Apr 18, 2007·Nature Reviews. Immunology·Warren D Shlomchik
Jan 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·W K SilversC F Barker
Apr 1, 1983·The Journal of Experimental Medicine·J W Streilein, P R Bergstresser
May 1, 1983·The Journal of Experimental Medicine·D Bellgrau
Dec 1, 1985·The Journal of Experimental Medicine·J Sprent, M Schaefer
Apr 1, 1990·The Journal of Experimental Medicine·J W Young, R M Steinman
Aug 27, 1997·Transplantation·W KrengerJ L Ferrara
Nov 5, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Isao TawaraPavan Reddy
May 1, 1986·The Journal of Clinical Investigation·D Guy-Grand, P Vassalli
Jun 10, 2010·The Journal of Clinical Investigation·Shoji AsakuraTakanori Teshima
Oct 9, 2014·Immunological Investigations·Youssef Mohamed Mosaad
Jun 13, 2009·Expert Opinion on Emerging Drugs·Yasser KhaledOleg Krijanovski
Oct 1, 1983·Clinics in Haematology·R Korngold, J Sprent
Dec 3, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sabarinath Venniyil RadhakrishnanGerhard C Hildebrandt
Mar 14, 2009·Lancet·James L M FerraraErnst Holler
May 28, 2008·Best Practice & Research. Clinical Haematology·Tomomi ToubaiPavan Reddy
Jul 1, 1983·Annales d'immunologie·H von BoehmerW Haas
Sep 29, 2007·Translational Research : the Journal of Laboratory and Clinical Medicine·Yaping SunPavan Reddy
Jan 1, 1986·International Journal of Cell Cloning·K M Sullivan
Jun 1, 1986·Immunological Reviews·J SprentR Korngold
Feb 1, 1984·Scandinavian Journal of Immunology·R Korngold, P C Doherty
Jul 1, 1984·The American Journal of Anatomy·J Clancy
Jan 1, 1983·Immunological Reviews·O RingdénS G Johansson
Sep 21, 2007·Cytotherapy·M P CollinM Merad
Apr 13, 2015·International Journal of Hematology·Muhammad Omer Jamil, Shin Mineishi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.